We are live on
!
Find out more
SCM
Stonepine Capital Management Portfolio holdings
AUM
$177M
1-Year Est. Return
91.13%
This Fund
S&P 500
This Quarter
Est. Return
+0.36%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$250M
AUM Growth
+$113M
(+82%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
101.74%
Top 10 Holdings %
Top 10 Hldgs %
70.9%
Holding
100
New
34
Increased
20
Reduced
25
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RADX
Radiopharm Theranostics
RADX
|
+$248M |
| 2 |
Tenax Therapeutics
TENX
|
+$13M |
| 3 |
CAMP4 Therapeutics
CAMP
|
+$5.51M |
| 4 |
Verastem
VSTM
|
+$3.52M |
| 5 |
Curis
CRIS
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Indivior Pharmaceuticals
INDV
|
+$3.59M |
| 2 |
Inhibikase Therapeutics
IKT
|
+$2.47M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$2.39M |
| 4 |
Eledon Pharmaceuticals
ELDN
|
+$2.02M |
| 5 |
Edesa Biotech
EDSA
|
+$1.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 54.47% |
| 2 | Healthcare | 45.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| $51.1M | 20.46% |
+400,000
| New | +$49.9M |
|
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
| $51.1M | 20.46% |
+400,000
| New | +$49.9M |
|
|
3
Verastem
VSTM
$743M
| $17.5M | 7.01% |
3,302,300
+570,221
| +21% | +$3.52M |
|
|
4
Tenax Therapeutics
TENX
$72.6M
| $15.6M | 6.24% |
975,200
+963,316
| +8,106% | +$13M |
|
5
CALL
ADMA Biologics
ADMA
$2.15B
| $10.4M | 4.15% |
+1,150,000
| New | +$18.1M |
|
6
Evolus
EOLS
$614M
| $7.23M | 2.9% |
1,759,091
+127,503
| +8% | +$618K |
|
|
7
ADMA Biologics
ADMA
$2.15B
| $6.67M | 2.67% |
740,000
| – | – |
|
|
8
CAMP4 Therapeutics
CAMP
$277M
| $6.13M | 2.45% |
1,389,622
+1,160,728
| +507% | +$5.51M |
|
9
Nektar Therapeutics
NKTR
$2.53B
| $6.12M | 2.45% |
85,000
| – | – |
|
|
TERN
10
CALL
DELISTED
Terns Pharmaceuticals
TERN
| $5.27M | 2.11% |
+100,000
| New | +$4.11M |
|
11
Zevra Therapeutics
ZVRA
$736M
| $4.47M | 1.79% |
480,000
-89,088
| -16% | -$803K |
|
12
Corbus Pharmaceuticals
CRBP
$214M
| $3.6M | 1.44% |
383,462
-6,454
| -2% | -$54.3K |
|
13
Abeona Therapeutics
ABEO
$343M
| $3.34M | 1.34% |
746,587
+37,082
| +5% | +$185K |
|
14
CALL
Establishment Labs
ESTA
$2.21B
| $2.84M | 1.14% |
+50,000
| New | +$3.41M |
|
|
KZIA
15
Kazia Therapeutics
KZIA
$191M
| $2.57M | 1.03% |
345,179
-115,180
| -25% | -$802K |
|
16
AN2 Therapeutics
ANTX
$222M
| $2.44M | 0.98% |
713,845
+86,177
| +14% | +$178K |
|
17
CALL
Alexandria Real Estate Equities
ARE
$9.06B
| $2.32M | 0.93% |
50,000
| – | – |
|
|
18
CALL
Acadia Pharmaceuticals
ACAD
$4.83B
| $2.23M | 0.89% |
+100,000
| New | +$2.39M |
|
19
Sol-Gel Technologies
SLGL
$228M
| $2.2M | 0.88% |
+27,778
| New | +$2.01M |
|
|
XOMA
20
DELISTED
Xoma
XOMA
| $2.18M | 0.87% |
69,500
-45,500
| -40% | -$1.22M |
|
21
AYTU BioPharma
AYTU
$23.7M
| $2.16M | 0.87% |
792,289
-21,415
| -3% | -$54.8K |
|
|
22
Curis
CRIS
$3.27M
| $2.04M | 0.82% |
186,320
+183,353
| +6,180% | +$3.41M |
|
|
23
CALL
Evolus
EOLS
$614M
| $1.73M | 0.69% |
+420,000
| New | +$2.04M |
|
24
CALL
Xeris Biopharma Holdings
XERS
$1.56B
| $1.62M | 0.65% |
+280,000
| New | +$1.86M |
|
25
TELA Bio
TELA
$36.9M
| $1.62M | 0.65% |
2,617,252
+265,220
| +11% | +$230K |
|
Similar funds
RP
MSA
HF
BFAG
CWP
MVM
CMP
JESC
Stonepine Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Stonepine Capital Management held 100 positions worth $250M, up 82% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Stonepine Capital Management deployed $254M of net new capital in Q1 2026, opening 34 new positions and adding to 20 existing holdings. Its largest new stake was Sol-Gel Technologies: 27,778 shares worth $2.2M.
By sector, the portfolio is most concentrated in Miscellaneous at 54% of assets, up from 7.7% a quarter earlier, followed by Healthcare.
On the sell side, the largest reduction was Inhibikase Therapeutics, an estimated $2.47M trimmed.
- Stonepine Capital Management's largest Q1 2026 buy was Sol-Gel Technologies: 27,778 shares worth $2.2M.
- Stonepine Capital Management added most to Radiopharm Theranostics in Q1 2026, an estimated $248M increase.
- Stonepine Capital Management's biggest Q1 2026 reduction was Inhibikase Therapeutics, cutting an estimated $2.47M.
- Stonepine Capital Management fully exited Indivior Pharmaceuticals in Q1 2026, selling an estimated $3.59M.
- Stonepine Capital Management's ten largest holdings make up 71% of its $250M portfolio in Q1 2026.
- Stonepine Capital Management opened 34 new positions and closed 17 in Q1 2026.
- Stonepine Capital Management's portfolio value rose 82% quarter-over-quarter to $250M.
Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.